Novartis's new chief sets sights on 'productivity revolution' | Financial Times
Novartis CEO Vas Narasimhan on M&A and Taking Earlier Risks on New Technology
Amazon.com: The Curious Advantage eBook : Ashcroft, Paul, Brown, Simon, Jones, Garrick: Kindle Store
Novartis CEO says company starting strategic review of Sandoz generic drug unit
Vas Narasimhan | LinkedIn
Novartis licenses phase 3 COVID-19 cell therapy from Mesoblast | Fierce Biotech
Novartis CEO Vas Narasimhan Sees Remote-Work Hybrid Persisting After Pandemic - Bloomberg
Novartis's Vas Narasimhan on AI, Data Science for Company Operations
Novartis says it knew of Zolgensma data problems before U.S. approval | The Japan Times
Novartis CEO Vasant Narasimhan on China's coronavirus outbreak
Novartis CEO Says FDA Process Could Have Been Handled Better - Bloomberg
Amazon Web Services, Google, Microsoft cloud: How cloud services are boosting the pharma sector - BusinessToday - Issue Date: Apr 16, 2023
We're energized by the opportunity to be a key digital partner for India' - About Amazon India
Novartis to Spin Alcon Unit, Launch $5 Billion Share Buyback | Fortune
Watch CNBC's full interview with Novartis CEO Vas Narasimhan - YouTube
Sunil Malewar | Paramount Rehabilitation Services
Novartis CEO Jimenez to step down early next year | The Seattle Times
The 'student' of leadership who seeks to inspire his employees | Financial Times
Novartis to limit M&A spend to 5% of market value | Financial Times
Klaus Moosmayer, Ph.D. | Novartis
Can you hear me, pharma? Voice-enabled apps are on the rise—and please don't freak out about privacy | Fierce Pharma
Don't foresee any disruptions due to Covid-19: Vasant Narasimhan, CEO, Novartis - The Economic Times
An Exciting Development, CRISPR Lets UW-Madison Researchers Edit Genes | Wisconsin Public Radio
